Health Care · Surgical & Medical Instruments & Apparatus

KRMD KORU Medical Systems, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 704440135 filings
Russell 2000

KRMD at a glance

KORU Medical Systems, Inc. (KRMD, SEC CIK 704440) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), KORU Medical Systems, Inc. (KRMD) reported revenue of $41.1 million (up 22.2% from FY2024) and a net loss of $2.6 million. Diluted EPS was -$0.06.
  • As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding KORU Medical Systems, Inc. (KRMD) shares worth $20.2 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Schiller Eric on November 13, 2026 of 8,546 shares at $3.63 per share.
  • In the last 90 days, KRMD insiders reported 2 open-market purchases ($132K) and 0 open-market sales ($0) on Form 4, a net purchase of $132K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$41.1M
+22.2% vs prior year
Insiders · 90 days
2 buys · 0 sells
Net +$132K
13F holders
20 funds
$20.2M · +0 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • Q2 revenue $12.0M, up 18.2% YoY from $10.2M
  • Gross margin 65.1% vs 63.5% YoY
  • Best segment International Core $3.5M, up 59.1% YoY
  • Worst segment Pharma Services $0.6M, down 35.0% YoY
  • Cash $8.3M; six-month operating cash flow $0.2M vs $(0.7)M YoY
  • Outlook: liquidity sufficient through next twelve months, with potential future debt or equity financing needs

Risk Factors

  • No material changes in risk factors identified; 10-Q references risks from the December 31, 2025 Form 10-K
  • Unregistered equity issuance risk from May 18 asset acquisition; 125,628 shares issued under Regulation D
  • Share-transfer restriction risk; issued shares subject to an 18-month transfer restriction

AI summary of the KRMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results covered quarter ended September 30, 2026
  • Updated fiscal 2026 guidance, potentially affecting earnings expectations and valuation

Item EX-99.1: Item EX-99.1

  • Q3 revenue $11.6M, up 11.2%, led by domestic core growth of 31.6% to $8.1M
  • Gross margin expanded to 65.2% from 60.2%, lifting gross profit 20.5% to $7.5M
Filed Aug 14, 2026Full analysis →

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Shareholder approval now required to remove directors, with majority of outstanding shares mandated
  • Board’s removal authority eliminated under amended Section 3.05
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $12.0M, up 18.2%, led by international core growth of 59.1% and domestic core growth of 12.4%
  • Gross margin improved to 65.1% from 63.5%, supporting gross profit growth of 21.2% to $7.8M

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results announced for quarter ended June 30, 2026, with investor call scheduled August 5
  • Fiscal 2025 guidance updated, potentially affecting earnings expectations and valuation

AI summaries of KRMD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for KRMD

Don't miss the next KRMD filing

  • Alerts as it files. A push when KRMD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut KRMD, by share count.
  • Ask anything. An AI agent that reads every KRMD filing and answers with sources.

KRMD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Manko Joseph M. Jr.JNov 20, 2026-
Schiller EricBuyNov 13, 2026$3.63
FLETCHER R JOHNAOct 1, 2026$2.93
French DonnaAOct 1, 2026$2.93
WHOLIHAN EDWARDAOct 1, 2026$2.93
CASCELLA ROBERTAOct 1, 2026$2.93
Matin ShahriarAOct 1, 2026$2.93
Manko Joseph M. Jr.ASep 30, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$28.5M$33.6M$41.1M
Gross Profit$16.7M$21.3M$25.6M
Operating Income--$6.4M-$3.0M
Net Income-$13.7M-$6.1M-$2.6M
Gross Margin58.6%63.4%62.3%
Op. Margin--19.2%-7.2%
Net Margin-48.2%-18.0%-6.4%
Balance Sheet
Total Assets-$27.2M$28.2M
Equity$20.4M$16.8M$17.0M
ROE-67.5%-36.1%-15.5%
Per Share
EPS-$-0.13$-0.06
Cash Flow
Operating CF--$320K$462K

Source: XBRL data in KORU Medical Systems, Inc. (KRMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate KRMD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
KRMD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202620$20.2M
Q2 202620$28.4M
Q1 202620$27.6M
Q4 202518$38.0M
Q3 202517$22.5M
Q2 202520$20.3M
Q1 202516$8.9M
Q4 202410$9.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 141 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

KRMD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 17, 2026--
8-KNov 10, 2026Analysis-
10-QNov 10, 2026-
4Oct 1, 2026--
4Oct 1, 2026--
4Oct 1, 2026--
4Oct 1, 2026--
4Oct 1, 2026--
4Oct 1, 2026--
4Sep 9, 2026--
8-KAug 14, 2026Analysis-
4Aug 6, 2026--
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
SC 13GJul 29, 2026-
4Jul 13, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
8-KJun 30, 2026Analysis-
4Jun 15, 2026--

Related Health Care companies

All Health Care →

KRMD SEC filings: frequently asked questions

Are KRMD insiders buying or selling?

In the last 90 days, KORU Medical Systems, Inc. (KRMD) officers, directors and 10% owners reported 2 open-market purchases worth $132,142 by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold KRMD stock?

As of September 30, 2026, the largest KORU Medical Systems, Inc. (KRMD) holders among the 13F filers tracked by SignalX were BlackRock ($8.2 million), Vanguard Capital Management LLC ($5.0 million), State Street Corp ($1.9 million), Northern Trust ($1.0 million), Vanguard Portfolio Management LLC ($895,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was KRMD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), KORU Medical Systems, Inc. (KRMD) reported revenue of $41.1 million (up 22.2% from FY2024) and a net loss of $2.6 million. Diluted EPS was -$0.06. The figures come from the XBRL data in the 10-K.

What did KRMD report in its latest 8-K?

KORU Medical Systems, Inc. (KRMD) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results covered quarter ended September 30, 2026.

What are the latest KRMD SEC filings?

KORU Medical Systems, Inc. (KRMD) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 20, 2026.

What is KRMD's SEC CIK number?

KORU Medical Systems, Inc. (KRMD)'s SEC Central Index Key (CIK) is 704440. EDGAR lists every KRMD filing under that number.

Ask anything about KRMD

The research agent reads KRMD's filings, financials, insider trades and 13F holders, then answers with sources.